Lykos Therapeutics PBC

Plus: CEO Amy Emerson steps down at Lykos, David Hough made CMO, and updates from Opthea, Modus, Melinta and more

Medicare drug prices revealed. Avoiding Lykos’ lapses. Translating from target to product

Functional unblinding, expectation bias are surmountable hurdles

At least 20 companies have trimmed pipelines, cut staff or otherwise re-jiggered strategies in past two weeks to extend runway

How Lykos MDMA-psychotherapy combination stumbled and why other psychedelic therapies won’t be affected

Committee advisers weren’t convinced Lykos’ psychotherapy combination is either effective or safe for PTSD

Plus: Lykos names CCO, VP, and an update from Iktos

Plus: Gilead’s $4.3B takeout of CymaBay

Second-generation psychedelics are being tested in more conventional clinical trials, and starting to yield impressive efficacy